This retrospective case series assessed the influence of unilateral intravitreal bevacizumab
(IVB) for unilateral type 1 retinopathy of prematurity (ROP) on macular thickness and foveal
development. Seven infants with unilateral type 1 ROP were treated with intravitreal
bevacizumab 0.625 mg/0.025 ml in one eye only. To determine whether macular thickness
and fovea structural development were affected by treatment, spectral domain optical
coherence tomography was performed on both treated and untreated eyes. The mean …

Purpose: Vascular endothelial growth factor inhibitors have become an alternative treatment
for retinopathy of prematurity (ROP), particularly for disease in zone I. The purpose of this
study is to assess the effect of intravitreal bevacizumab on foveal development and macular
thickness in infants treated for type 1 retinopathy of prematurity for unilateral disease and
compare treated and untreated eyes of the same infant. Methods: This is a retrospective
case-series of all infants treated with intravitreal bevacizumab (IVB) 0.625 mg/0.025 ml for …